We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Surge in Adoption of Next-Gen Non-Invasive DNA Tests for High-Risk Pregnancies to Drive NIPT Market

By LabMedica International staff writers
Posted on 07 Oct 2022

The global non-invasive prenatal testing (NIPT) market is projected to register a CAGR of 14. More...

8% between 2022 and 2031 to reach USD 8.4 billion by the end of 2031, driven by an increase in the prevalence of Turners' syndrome and Down's syndrome among newborn babies, as well as a surge in the adoption of next-gen non-invasive DNA tests in high-risk pregnancies.

These are the latest findings of Transparency Market Research (Wilmington, DE, USA), a global market research company.

There has been a rise in cases of Down's syndrome and Turners' syndrome among newborn babies globally which is driving demand in the NIPT market. The popularity of NIPT has been increasing in recent years owing to the ability of this procedure to provide precise test results within a short duration. As a result, the growing adoption of testing is creating lucrative growth prospects for the NIPT market.

Additionally, governments in several countries are implementing favorable policies to provide complete reimbursement of NIPT in the second trimester, resulting in a rise in the adoption of such tests. Moreover, regulatory authorities in several countries are focusing on offering reimbursement for different tests, including non-invasive prenatal tests for chromosomal health issues such as Down's syndrome. These efforts are expected to drive sales of the global NIPT market.

Going forward, growing preference among healthcare professionals for performing next-gen non-invasive DNA tests for high-risk pregnancies is expected to drive sales of the NIPT market. Further, the increasing trend of delaying pregnancy among couples is anticipated to fuel market growth. Also, a surge in the prevalence of pregnancy-related problems in the second or third trimester is likely to contribute to the market growth.

Geographically, the North American NIPT market is anticipated to register the strongest growth during the forecast period owing to an increase in diagnosis and treatment of trisomy health issues, the presence of several key players, and existence of a well-established healthcare infrastructure in the U.S. The Asia Pacific NIPT market is expected to expand at a fast pace due to an increase in maternal age in the region, which can lead to a rise in cases of chromosomal aneuploidies among babies.

Related Links:
Transparency Market Research 


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
Blood Glucose Test Strip
AutoSense Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.